What are the main functions and effects of Pitobrutinib/Pitobrutinib?

Pirtobrutinib is an oral small molecule kinase inhibitor that belongs to the Bruton's tyrosine kinase (BTK) inhibitor family. It is mainly used for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Compared with traditional BTK inhibitors, pitubrutinib uses a non-covalent binding mechanism, so it can continue to exert its efficacy in patients who have experienced previous BTK inhibitor treatment failure, providing a new treatment option for relapsed or refractory patients.

The drug blocks the abnormal activation of B cell receptor signals by targeting theBTK signaling pathway, thereby inhibiting the proliferation and survival of cancerous B cells. This is particularly critical for patients with mantle cell lymphoma and CLL/SLL, as these diseases are often accompanied by abnormal B cell signaling, leading to increased risk of disease progression and relapse. Pitobrutinib's mechanism can not only inhibit the growth of tumor cells, but also regulate the immune microenvironment, making the anti-cancer effect more comprehensive. In addition, the convenience of oral administration improves patient compliance and reduces the burden of hospitalization and infusion compared with traditional injection or intravenous chemotherapy regimens.

Clinical observations show that pitubrutinib can improve hematology and imaging, alleviate symptoms, and extend progression-free survival in relapsed or refractory patients. At the same time, due to its non-covalent binding properties, the drug is still effective against tumor cells with drug-resistant BTK mutations, which is also the core advantage of its application in relapsed/refractory cases. Overseas guidelines recommend pitubrutinib as one of the treatment options for adult patients with MCL or CLL/SLL who have previously received at least two lines of systemic therapy (including BTK inhibitors). It can effectively enrich individualized treatment strategies and provide more clinical flexibility.

Reference materials:https://go.drugbank.com/drugs/DB17472